PMID- 34680473
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211026
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 9
IP  - 10
DP  - 2021 Sep 29
TI  - Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function.
LID - 10.3390/biomedicines9101356 [doi]
LID - 1356
AB  - Type 2 diabetes mellitus (T2DM) is a known independent risk factor for 
      atherosclerotic cardiovascular disease (CVD) and solid epidemiological evidence 
      points to heart failure (HF) as one of the most common complications of diabetes. 
      For this reason, it is imperative to consider the prevention of CV outcomes as an 
      effective goal for the management of diabetic patients, as important as lowering 
      blood glucose. Endothelial dysfunction (ED) is an early event of atherosclerosis 
      involving adhesion molecules, chemokines, and leucocytes to enhance low-density 
      lipoprotein oxidation, platelet activation, and vascular smooth muscle cell 
      proliferation and migration. This abnormal vascular phenotype represents an 
      important risk factor for the genesis of any complication of diabetes, 
      contributing to the pathogenesis of not only macrovascular disease but also 
      microvascular damage. Gliflozins are a novel class of anti-hyperglycemic agents 
      used for the treatment of Type 2 diabetes mellitus (T2DM) that selectively 
      inhibit the sodium glucose transporter 2 (SGLT2) in the kidneys and have provoked 
      large interest in scientific community due to their cardiovascular beneficial 
      effects, whose underlying pathophysiology is still not fully understood. This 
      review aimed to analyze the cardiovascular protective mechanisms of SGLT2 
      inhibition in patients T2DM and their impact on endothelial function.
FAU - Salvatore, Teresa
AU  - Salvatore T
AD  - Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via De 
      Crecchio 7, I-80138 Naples, Italy.
FAU - Caturano, Alfredo
AU  - Caturano A
AUID- ORCID: 0000-0001-7761-7533
AD  - Department of Advanced Medical and Surgical Sciences, University of Campania 
      Luigi Vanvitelli, Piazza Luigi Miraglia 2, I-80138 Naples, Italy.
FAU - Galiero, Raffaele
AU  - Galiero R
AD  - Department of Advanced Medical and Surgical Sciences, University of Campania 
      Luigi Vanvitelli, Piazza Luigi Miraglia 2, I-80138 Naples, Italy.
FAU - Di Martino, Anna
AU  - Di Martino A
AD  - Department of Advanced Medical and Surgical Sciences, University of Campania 
      Luigi Vanvitelli, Piazza Luigi Miraglia 2, I-80138 Naples, Italy.
FAU - Albanese, Gaetana
AU  - Albanese G
AD  - Department of Advanced Medical and Surgical Sciences, University of Campania 
      Luigi Vanvitelli, Piazza Luigi Miraglia 2, I-80138 Naples, Italy.
FAU - Vetrano, Erica
AU  - Vetrano E
AD  - Department of Advanced Medical and Surgical Sciences, University of Campania 
      Luigi Vanvitelli, Piazza Luigi Miraglia 2, I-80138 Naples, Italy.
FAU - Sardu, Celestino
AU  - Sardu C
AD  - Department of Advanced Medical and Surgical Sciences, University of Campania 
      Luigi Vanvitelli, Piazza Luigi Miraglia 2, I-80138 Naples, Italy.
FAU - Marfella, Raffaele
AU  - Marfella R
AUID- ORCID: 0000-0003-3960-9270
AD  - Department of Advanced Medical and Surgical Sciences, University of Campania 
      Luigi Vanvitelli, Piazza Luigi Miraglia 2, I-80138 Naples, Italy.
FAU - Rinaldi, Luca
AU  - Rinaldi L
AUID- ORCID: 0000-0002-6541-3821
AD  - Department of Advanced Medical and Surgical Sciences, University of Campania 
      Luigi Vanvitelli, Piazza Luigi Miraglia 2, I-80138 Naples, Italy.
FAU - Sasso, Ferdinando Carlo
AU  - Sasso FC
AUID- ORCID: 0000-0002-9142-7848
AD  - Department of Advanced Medical and Surgical Sciences, University of Campania 
      Luigi Vanvitelli, Piazza Luigi Miraglia 2, I-80138 Naples, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210929
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC8533063
OTO - NOTNLM
OT  - cardiovascular diseases
OT  - endothelial dysfunction
OT  - gliflozins
OT  - heart prevention
COIS- The authors declare no conflict of interest.
EDAT- 2021/10/24 06:00
MHDA- 2021/10/24 06:01
PMCR- 2021/09/29
CRDT- 2021/10/23 01:04
PHST- 2021/08/11 00:00 [received]
PHST- 2021/09/15 00:00 [revised]
PHST- 2021/09/26 00:00 [accepted]
PHST- 2021/10/23 01:04 [entrez]
PHST- 2021/10/24 06:00 [pubmed]
PHST- 2021/10/24 06:01 [medline]
PHST- 2021/09/29 00:00 [pmc-release]
AID - biomedicines9101356 [pii]
AID - biomedicines-09-01356 [pii]
AID - 10.3390/biomedicines9101356 [doi]
PST - epublish
SO  - Biomedicines. 2021 Sep 29;9(10):1356. doi: 10.3390/biomedicines9101356.